129 Xenon Imaging in Patients Treated With Sotatercept
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBastiaan Driehuys
About this trial
Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).
Eligibility criteria
Qualifiers
Outpatients of either gender, Age 18-75
Diagnosis of precapillary PH (right heart catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure (mPAP) ≥ 20 mmHg, pulmonary vascular resistance ≥ 5 WU, pulmonary capillary wedge pressure ≤ 15 mmHg) in the setting of Group 1 (PAH)
Willing and giving informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).
On a stable dose of background PAH therapy for > 90 days prior to study enrollment
Disqualifiers
Moderate to severe heart disease (LVEF < 45%, Severe LV hypertrophy, Moderate to severe valvular disease)
Chronic thromboembolic disease
PH due to schistosomiasis
Active cancer
Trial design
Treatments tested in this trial
- 129Xe Hyperpolarized
Treatment groups
14 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov